Posted by Michael Wonder on 08 Jul 2019
SMC - July 2019 decisions
8 July 2019 - A medicine used to treat advanced breast cancer has today been accepted by the Scottish Medicines Consortium for use in NHSScotland.
Palbociclib (Ibrance), used in combination with another medicine, fulvestrant, was accepted following consideration through the SMC’s Patient and Clinician Engagement (PACE) process, which is used for medicines to treat end of life and very rare conditions.
Daratumumab (Darzalex) for the treatment of multiple myeloma was also accepted through PACE.
